Nitrofurantoin Pharmsol (Nitrofurantoin)

Nitrofurantoin is converted by bacterial enzymes into reactive intermediates that bind to DNA and other macromolecules, causing damage that inhibits bacterial replication and leads to cell death. The drug concentrates in the urinary tract, providing targeted antibacterial activity.

The dosage of Nitrofurantoin Pharmsol is determined by the prescribing clinician based on the patient’s condition, renal function, and local treatment guidelines. The prescriber will select the appropriate strength, frequency, and duration for each individual case.

Safety of Nitrofurantoin Pharmsol in pregnancy or while breastfeeding has not been definitively established. It should be used only when clearly needed and after careful risk‑benefit assessment by the healthcare provider.

To order Nitrofurantoin Pharmsol, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative for uncomplicated urinary tract infections is trimethoprim‑sulfamethoxazole. Nitrofurantoin offers a different mechanism of action and is less likely to encounter resistance in many regions, but it requires adequate renal function for urinary concentration, whereas trimethoprim‑sulfamethoxazole has broader systemic activity.

Store Nitrofurantoin Pharmsol at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme heat to maintain stability and potency throughout its shelf life.

Nitrofurantoin Pharmsol is taken orally, usually with food or a full glass of water to reduce gastrointestinal irritation. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include pulmonary toxicity (interstitial pneumonitis or fibrosis), hepatic injury, severe allergic reactions such as Stevens‑Johnson syndrome, and hemolytic anemia in patients with G6PD deficiency. Patients should seek immediate medical attention if they experience breathing difficulty, jaundice, rash, or dark urine.

Nitrofurantoin Pharmsol should be avoided in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin, G6PD deficiency, or in those who have experienced serious pulmonary or hepatic reactions to the drug.